Overview

Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients

Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
A 2-year multicenter, phase II/III, randomized active-controlled trial to evaluate the efficacy and tolerance of two maintenance strategies in HIV-1 infected patients with HIV RNA below 50 copies/mL : a monotherapy with lopinavir/ritonavir or a single-tablet triple therapy (EFV/FTC/TDF).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Collaborators:
Abbott
Gilead Sciences
Treatments:
Efavirenz
Lopinavir
Ritonavir
Tenofovir